These findings underscore the promise of GSK2606414 and cisplatin co-treatment as a potent strategy to counteract ovarian cancer resistance. This combination could potentially advance therapeutic outcomes and provide a new pharmacological approach to resistant cancers.

4 months ago

Journal

MSH3 (MutS Homolog 3) • CASP12 (Caspase 12 (Gene/Pseudogene))

cisplatin • GSK2606414

5ms

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With Steroid-refractory aGVHD. (clinicaltrials.gov)

P1, N=24, Recruiting, Accro Bioscience (Suzhou) Limited

5 months ago

New P1 trial

5ms

RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target. (PubMed, Int J Mol Sci)

Transcriptomic studies were carried out using USC Xena and R, while in vitro assays were performed with the glioblastoma human cell line U251 and the commercial RIPK1 inhibitor GSK2982772...To further characterize the role of RIPK1 in DG, the effects of the RIPK1 inhibitor were evaluated, alone or combined with cisplatin, on glioblastoma cell proliferation and apoptosis. The combined treatments effectively reduced cell proliferation and increased apoptosis. The overexpression of RIPK1 was associated with a poor prognosis for DG, suggesting that RIPK1 plays a critical role in glioma pathogenesis and should be considered in therapeutic decision-making.

5 months ago

Journal

RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)

cisplatin

5ms

ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis. (PubMed, Biochem Pharmacol)

This was characterized by heightened necroptosis activation, reduced cell viability, and increased apoptosis. These findings expand our understanding of the interaction between DNA damage and cell death regulation and may aid in developing therapeutic drugs to enhance DNA damage-induced tumor necroptosis and improve chemosensitivity.

5 months ago

Journal

ATR (Ataxia telangiectasia and Rad3-related protein) • CDK7 (Cyclin Dependent Kinase 7) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)

6ms

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)

P1, N=7, Completed, Genentech, Inc. | Terminated --> Completed

6 months ago

Trial completion

8ms

ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis. (PubMed, Biochem Pharmacol)

8 months ago

Journal

ATR (Ataxia telangiectasia and Rad3-related protein) • CDK7 (Cyclin Dependent Kinase 7) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)

8ms

RESOLUTE: Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (clinicaltrials.gov)

P2, N=182, Recruiting, Sanofi | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Feb 2026

8 months ago

Trial completion date • Trial primary completion date

10ms

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) (clinicaltrials.gov)

P2, N=404, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting

10 months ago

Enrollment open • Adverse events

11ms

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)

P2, N=30, Completed, AbbVie | Active, not recruiting --> Completed

11 months ago

Trial completion

12ms

ACT16753: A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis (clinicaltrials.gov)

P2, N=174, Terminated, Sanofi | Trial completion date: Sep 2025 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Nov 2024; The study was terminated as it did not meet its primary and key secondary endpoints

12 months ago

Trial completion date • Trial termination • Trial primary completion date